Anthera Pharmaceuticals Inc (ANTH)

OTC Markets
0.000
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    0.000 - 0.000

ANTH Overview

Prev. Close
-
Day's Range
-
Revenue
-
Open
-
52 wk Range
0-0.066
EPS
-1.69
Volume
0
Market Cap
26
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
9,420
P/E Ratio
-
Beta
-
1-Year Change
-95.45%
Shares Outstanding
26,179,302
Next Earnings Date
Aug 10, 2022
What is your sentiment on Anthera Pharma?
or
Market is currently closed. Voting is open during market hours.

Anthera Pharmaceuticals Inc News

Anthera Pharmaceuticals Inc Analysis

Anthera Pharmaceuticals Inc Company Profile

Anthera Pharmaceuticals Inc Company Profile

Employees
21

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong Sell
Technical IndicatorsNeutralStrong Sell
SummarySellStrong Sell